[Thromboembolism in non-rheumatic atrial fibrillation].
Pengo
V
V
Dipartimento di Medicina Clinica e Sperimentale, Università di Padova.
D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000150:complications* / Q000453:epidemiology / Q000628:therapy; D002986:Clinical Trials as Topic; D003245:Consensus Statements as Topic; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D004554:Electric Countershock; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D015994:Incidence; D019934:International Normalized Ratio; D007527:Isoenzymes / Q000037:antagonists & inhibitors; D054833:Isoindoles; D008297:Male; D008565:Membrane Proteins; D008875:Middle Aged; D010654:Phenylbutyrates / Q000009:adverse effects / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D011446:Prospective Studies; D011451:Prostaglandin-Endoperoxide Synthases; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D020521:Stroke / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D013923:Thromboembolism / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control; D016896:Treatment Outcome; D014859:Warfarin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use
D000925:Anticoagulants; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D054833:Isoindoles; D008565:Membrane Proteins; D010654:Phenylbutyrates; D010975:Platelet Aggregation Inhibitors; D014859:Warfarin; C020371:indobufen; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases; D001241:Aspirin
Tromboembolismo nella fibrillazione atriale non-reumatica.